市場進入的影響 (EU5個國家):第二型糖尿病 (口服藥)
Market Access Impact: Type 2 Diabetes Mellitus [Orals] (EU5) 2018
|市場進入的影響 (EU5個國家):第二型糖尿病 (口服藥) Market Access Impact: Type 2 Diabetes Mellitus [Orals] (EU5) 2018|
|出版日期: 2018年04月01日||內容資訊: 英文||
本報告依據歐洲主要5個國家從事第二型糖尿病的治療的150名醫療專家的問卷調查結果，提供糖尿病的治療藥 (口服藥)的採購、使用相關問題點相關分析，基本的市場結構和主要企業、品牌的市場佔有率，各公司現在面臨的主要障礙 (市場進入等)，障礙的主要原因 (各種法規等)，應採取對策的資訊彙整，為您概述為以下內容。
Market barriers affect a fifth of oral diabetes treatment prescriptions in Europe. Is your brand losing out?
Market barriers affect over a fifth of all oral type 2 diabetes mellitus (T2DM) prescriptions in Europe, and certain brands are losing out on market share big time. Is it yours? Find out what's driving share gains, and what your brand can do to level the playing field in Market Access Impact: Type 2 Diabetes Mellitus (Orals) (EU5) .
Based on a survey of 150 European diabetologists from the leading EU5 markets (France, Germany, Italy, Spain, and the UK), the report covers 9 major oral therapies from AstraZeneca, Eli Lilly, Boehringer Ingelheim, Janssen Cilag, Merck Sharp & Dohme, and Takeda. Handy graphs and charts reveal which of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.
Insight into 9 Oral Type 2 Diabetes Mellitus Treatments
Exploring Market Access Barriers
Market Access Impact: Type 2 Diabetes Mellitus [Orals] (EU5) explores key issues affecting type 2 diabetes mellitus drug manufacturers. You'll learn:
How barriers affect market access:
How barriers affect your brand:
A Report Based on Expert Knowledge
We surveyed 150 diabetologists and primary care physicians-30 from each EU5 country (France, Italy, Germany, Spain, UK)-chosen from the largest community of validated physicians in the world. All respondents have:
We conducted the survey between April 5-10, 2018.
Money Back Guarantee!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Learn more at www.firstwordgroup.com.